





Genomic Health INC
Rank 12 of 72

The relative strengths and weaknesses of Genomic Health INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Genomic Health INC compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 102% points. The greatest weakness of Genomic Health INC is the variable Selling and Marketing Expense, reducing the Economic Capital Ratio by 73% points.

The company's Economic Capital Ratio, given in the ranking table, is 245%, being 84% points above the market average of 161%.

Input Variable	Value in 1000 USD
Assets, Current	128,995
Assets, Non-Current	4,560
Cost of Goods and Services Sold	0
Depreciation, Depletion, Amortization	0
General and Administrative Expense	40,543
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	26,139
Long Term Liabilities	0
Operating Costs and Expenses	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	34,261
Other Liabilities	0
Other Net Income	16
Other Revenues	206,111
Property Plant and Equipment	9,443
Research And Development Expense	39,864
Selling and Marketing Expense	83,613

Output Variable	Value in 1000 USD
Assets	142,998
Liabilities	26,139
Expenses	198,281
Revenues	206,111
Stockholders Equity	116,859
Net Income	7,846
Comprehensive Net Income	7,846
BaseVar	286,772
ECR before LimitedLiability	210%
Economic Capital Ratio	245%